On the stock market since 2014, it operates in the world of health and science. It has 2,475 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 12% a year over the last 4 years. Every year shown ended in profit.
The gap is $684.5M. In times of high interest rates, a gap like that can squeeze a company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
The price looks reasonable next to what the company earns.
Sales are growing strongly for its sector.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Executive Buying: The trades send no strong signal of confidence.
The stock trades 44% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 11% a year on average.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
The average analyst price target is $49.00 — 47% above today’s price.
Over the last 12 months, executives reported 130 sells against just 14 buys. Not an alarm bell by itself, but a number worth watching.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 30/100. For a turnaround signal, the stock first needs to close the gap with the market.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 36/100.
On our five-subject report card, PAHC sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: PAHC is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.